Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
about
Memantine for dementiaWithdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementiaWithdrawal versus continuation of chronic antipsychotic drugs for behavioural and neuropsychiatric symptoms in elderly patients with dementiaMemantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's diseaseMemantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalitiesCourse, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Parkinson's psychosis.A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.Neuropsychiatric profiles in dementia.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity.Outcomes for assessment of symptomatic and stabilization/disease modifying drugs.Present and prospective clinical therapeutic regimens for Alzheimer's disease.The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I.Pharmacotherapy of Alzheimer disease.Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease.Current therapeutic options for Alzheimer's diseaseMemantine: efficacy and safety in mild-to-severe Alzheimer's disease.Inflammation and aging: can endocannabinoids help?New approaches to the treatment of frontotemporal lobar degeneration.Current concepts in Alzheimer's disease: a multidisciplinary review.Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.Management of behavioral problems in Alzheimer's disease.Memantine in dementia: a review of the current evidence.The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysisBehavioral and psychological subsyndromes in Alzheimer's disease using the Neuropsychiatric Inventory.Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.Late-life psychosis: diagnosis and treatment.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
P2860
Q22252980-DFD5C481-334B-466D-BBF1-52D9228E408EQ24198248-CCE7D296-3B49-4CA8-8423-0080ED13A051Q24240400-4D316145-3447-4F7E-B8BC-D810E4FAAE10Q27025207-2B042B6C-9C32-48FC-9734-EB6B0E8CADC7Q33597194-1CE49374-6CFA-413C-8CFE-A5B73B899B2AQ33630085-B1423987-1706-4983-B3F2-2C92501BE844Q34222721-8A524EF1-1F11-4EB8-932D-A39B658B7164Q34328295-067E5D7A-F937-455C-9745-BC1E8189CF74Q34409349-5253F002-B473-47DC-8649-510314580DBAQ34552380-487666CE-60AD-470C-9F92-5BA2134D933AQ34610593-7C7F4EF0-83B1-470F-9ECA-1BA724F55C51Q34610632-70A68805-1F95-4C03-8E55-943A8B419472Q34977044-E8B6E78D-4F6F-42F3-BB40-E3B076F0C787Q35107027-84A7974B-6EF7-4D8B-9389-634C7D19986AQ35117821-E51B3AA7-2605-4185-8F66-88A512E6627EQ35556420-6FC63909-DC2F-4471-AA56-7F11F76548BAQ36310524-166BA5C2-95A3-48F0-9A97-2D46B7BC3106Q36403620-174B6278-2B84-47BB-A117-AA38244213A4Q36713096-A02D852E-E47B-4B27-B611-39927E3E42BAQ36806602-84D18B77-9178-485B-AECF-4E18E930FDEFQ36876447-1F50F6D0-2416-4262-849C-14A939E89AD1Q36923575-817A04DE-AD9F-4EDF-BFF6-13841E60B216Q36978027-5C9E989B-79B8-4F55-B2B2-9A105E47D7B8Q36994937-3718C526-F3DE-476F-98D0-75ABA81422DCQ37004359-A32C88FD-ED91-44A1-916B-BC6116F1662EQ37004363-35071533-A5FC-4F03-B2DE-0B4A5824F633Q37103064-4C263349-B900-4331-86A8-2DEDB2DED551Q37108146-1CD602E1-73C5-49D3-A21A-A1FBB3544C65Q37125743-AA18FA32-3E40-48EA-B66B-279E96B10E1CQ37133525-7A6A7805-E8BA-4DBA-83BC-09313482C407Q37319294-55327AE5-0D72-40E1-A0C1-86D788568D16Q37360292-CE7F0760-9F7A-422B-A5D7-15A65EA8A16DQ37388456-4C371194-FAEB-4EF7-A2FA-E8C7753DF9FEQ37680018-8CB6761E-0BFC-43E8-946D-2D36BECEF603Q37850821-E390029D-4AD8-4A96-B9AA-06A3719258FCQ37967728-356AB00E-EEA1-447F-BF4D-C3657BDEDF08Q38059401-313309B6-7B0F-4903-9833-0BE7B5B4F25BQ38066972-E51F1B52-D612-4384-A508-3838A7C33E6CQ38330595-29C880AB-CBD2-41DC-A8AB-04A921C02810Q38661735-3BC73D2B-9AC3-4D87-B34D-FC10A2638011
P2860
Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effects of memantine on behavi ...... andomised, controlled studies.
@ast
Effects of memantine on behavi ...... andomised, controlled studies.
@en
type
label
Effects of memantine on behavi ...... andomised, controlled studies.
@ast
Effects of memantine on behavi ...... andomised, controlled studies.
@en
prefLabel
Effects of memantine on behavi ...... andomised, controlled studies.
@ast
Effects of memantine on behavi ...... andomised, controlled studies.
@en
P2093
P2860
P356
P1476
Effects of memantine on behavi ...... andomised, controlled studies.
@en
P2093
P2860
P304
P356
10.1002/GPS.1341
P407
P577
2005-05-01T00:00:00Z